Furthermore, next-generation biomarkers for screening, diagnosis, and prognostic assessment of HF, such as soluble sources of tumorigenicity 2 (sST2), galectin-3 (Gal-3), and growth differentiation factor-15 (GDF-15), have showed promising applications [103,104,105]. This evidence concerns the gene GDF15 and hydrops fetalis.